Medivir—winner of the SwedenBIO Award 2010

Medivir—winner of the SwedenBIO Award 2010

Today, Medivir's CEO Ron Long received the SwedenBIO Award 2010 from
research and further education minister Tobias Krantz at life sciences
industry organization SwedenBIO's annual conference in Stockholm.

Medivir won the award for all the successes the company achieved in
2009. The citation for Medivir, worthy winner of the SwedenBIO Award
2010, reads as follows: 
Citation
During the year, management positioned the company to evolve from a
research and development enterprise into a pharmaceutical company with
proprietary products and its own Nordic sales organization. Its new cold
sore product Xerclear™ is the first, and so far only, pharmaceutical
able to demonstrate in clinical trials that it can prevent the incidence
of cold sores, a condition affecting 2 million people in Sweden alone.
Medivir secured market approval on its two key markets of the US and
Europe in 2009, with unique competitive advantages. At the same time,
the company built its own sales organization, while also achieving
substantial advances in international partnerships with other companies,
particularly in the hepatitis C segment. Perseverance, partnership and a
global perspective are the core ingredients of Medivir's recipe for
success. 
“2009 was a year Medivir made a lot of progress on the road to becoming
an established pharmaceutical company. It's really stimulating from me
and my colleagues to receive the SwedenBIO Award with this citation,”
commented Medivir's CEO Ron Long.

For financial information, please contact
Rein Piir, Medivir's CFO and VP of Investor Relations,
Tel: +46 (0) 708-537 292.